Capella

Capella—the Online Voice of Progress in RNAi

Welcome to Capella, Alnylam’s destination for updates on our work translating the breakthrough discovery of RNA interference (RNAi) into an innovative new class of medicines. We’ve been pioneering RNAi therapeutics since 2002 and are excited to share our ongoing scientific progress.

11 Nov, 2023 New Results from KARDIA-1 Phase 2 Study of Zilebesiran Presented at the American Heart Association (AHA) Scientific Sessions 2023

Posted at 17:00:15 h

New results from the KARDIA-1 Phase 2 study of zilebesiran, an investigational RNAi therapeutic targeting liver-expressed angiotensinogen (AGT) in development for the treatment of patients with hypertension and high cardiovascular risk, were presented at the American Heart Association (AHA) Scientific Sessions 2023.
Bakris, et al. “Sustained Blood Pressure Reduction with the RNA Interference Therapeutic, Zilebesiran: Primary Results from KARDIA-1, a Phase 2 Study in Patients with Hypertension”

Read More
03 Nov, 2023 24-Month Results from ILLUMINATE-C Phase 3 Study of OXLUMO® (lumasiran) Presented at the American Society of Nephrology (ASN) Kidney Week 2023 Meeting

Posted at 13:08:49 h

New 24-month results from the ILLUMINATE-C Phase 3 study of lumasiran in patients with advanced primary hyperoxaluria type 1 (PH1) were presented at the American Society of Nephrology (ASN) Kidney Week 2023 Meeting. Additional findings from a retrospective study of the natural history of advanced PH1 were also presented.
Lieske, et al. “Lumasiran for Primary Hyperoxaluria Type 1 and Impaired Kidney Function: 24-Month Analysis of the Phase 3 ILLUMINATE-C Trial”
Lieske, et al. “Natural History of Advanced Primary Hyperoxaluria Type 1: A Retrospective Study”

Read More
25 Oct, 2023 APOLLO-B Phase 3 Study Results Published in the New England Journal of Medicine

Posted at 17:05:35 h

Results from the APOLLO-B Phase 3 study of investigational patisiran in patients with the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis were published in the New England Journal of Medicine.
Read the manuscript

Read More
25 Oct, 2023 New Phase 1 Results for ALN-APP Presented at Clinical Trials on Alzheimer’s Disease Conference

Posted at 11:06:52 h

We presented additional positive interim results for the ongoing single ascending dose portion of the Phase 1 study of ALN-APP, an investigational RNAi therapeutic targeting amyloid precursor protein in development for the treatment of Alzheimer’s disease and cerebral amyloid angiopathy, in a late-breaker session at the 16^th Clinical Trials on Alzheimer’s Disease conference.
Mummery, et al. “Phase 1 Safety, Tolerability, and Pharmacological Results of ALN-APP, the First Investigational RNA Interference Therapeutic in Development for Early-Onset Alzheimer’s Disease”

Read More
08 Oct, 2023 New Results for Patisiran Presented during HFSA ASM 2023

Posted at 08:37:37 h

New 24-month results from an interim analysis of the open-label extension period of the APOLLO-B Phase 3 study of patisiran in patients with the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis were presented at the Heart Failure Society of America (HFSA) Annual Scientific Meeting (ASM) 2023. Findings from a post-hoc analysis of the APOLLO-B Phase 3 study that further characterize the impact of patisiran on health status and quality of life in patients with the cardiomyopathy of ATTR amyloidosis were also presented, as well as an overview of baseline characteristics of patients who enrolled in the expanded access program for patisiran.
Maurer, et al. “Primary Results from APOLLO-B Open-label Extension Study of Patisiran in Patients with Transthyretin Cardiac Amyloidosis”
Shah, et al. “Impact of Patisiran on Health Status and Quality of Life in Patients with Transthyretin Cardiac Amyloidosis”
Saha, et al. “Baseline Characteristics of Patients with Transthyretin Cardiac Amyloidosis Enrolled in the Patisiran Expanded Access Program”

Read More
10 Sep, 2023 New Results from Phase 1 Study of Zilebesiran Presented at American Heart Association Hypertension Scientific Sessions 2023

Posted at 16:11:18 h

New results from Part D of the Phase 1 study of zilebesiran, assessing the safety and pharmacology of sequential doses of zilebesiran in patients with Class II or III obesity, were presented during the American Heart Association Hypertension Scientific Sessions 2023.
Taubel, et al. “Safety and Tolerability of Zilebesiran, an RNAi Interference Therapeutic Targeting Hepatic Angiotensinogen Synthesis, in Obese Patients with Hypertension”

Read More
26 Aug, 2023 New Results from Post Hoc Analysis of APOLLO-B Phase 3 Study of Patisiran Presented during ESC 2023

Posted at 11:33:13 h

New results from a post hoc analysis of the APOLLO-B Phase 3 study of patisiran in patients with ATTR amyloidosis with cardiomyopathy evaluating disease progression following 12 months of treatment with patisiran vs. placebo were presented during the European Society of Cardiology (ESC) Congress 2023.
Damy, et al. “Evaluation of Disease Progression in Patients with ATTR Amyloidosis with Cardiomyopathy Following Treatment with Patisiran: Post hoc Analysis of the APOLLO-B Study”

Read More
02 Aug, 2023 Phase 3 Results From ENVISION Study of GIVLAARI® (givosiran) Published in the Journal of Hepatology

Posted at 12:55:05 h

Results from the Phase 3 ENVISION study of GIVLAARI^® (givosiran) in adult patients with acute hepatic porphyria (AHP) were published in the Journal of Hepatology.
Read the manuscript

Read More
19 Jul, 2023 Phase 1 Results of Zilebesiran Published in the New England Journal of Medicine

Posted at 17:11:50 h

Results from the Phase 1 study of zilebesiran, an investigational RNAi therapeutic targeting liver-expressed angiotensinogen (AGT) in development for the treatment of hypertension, were published in the New England Journal of Medicine (NEJM).
Read the manuscript

Read More
17 Jul, 2023 Updated Phase 1 Results for ALN-APP Presented at 2023 Alzheimer’s Association International Conference

Posted at 02:23:32 h

We presented updated positive interim results for the ongoing single ascending dose portion of the Phase 1 study of ALN-APP, an investigational RNAi therapeutic targeting amyloid precursor protein (APP) in development for the treatment of Alzheimer’s disease and cerebral amyloid angiopathy (CAA), at the 2023 Alzheimer’s Association International Conference (AAIC).
Cohen et al. “Interim Phase 1 Part A Results for ALN-APP, the First Investigational RNAi Therapeutic in Development for Alzheimer’s Disease”

Read More

Capella

Capella—the Online Voice of Progress in RNAi

11 Nov, 2023 New Results from KARDIA-1 Phase 2 Study of Zilebesiran Presented at the American Heart Association (AHA) Scientific Sessions 2023

03 Nov, 2023 24-Month Results from ILLUMINATE-C Phase 3 Study of OXLUMO® (lumasiran) Presented at the American Society of Nephrology (ASN) Kidney Week 2023 Meeting

25 Oct, 2023 APOLLO-B Phase 3 Study Results Published in the New England Journal of Medicine

25 Oct, 2023 New Phase 1 Results for ALN-APP Presented at Clinical Trials on Alzheimer’s Disease Conference

08 Oct, 2023 New Results for Patisiran Presented during HFSA ASM 2023

10 Sep, 2023 New Results from Phase 1 Study of Zilebesiran Presented at American Heart Association Hypertension Scientific Sessions 2023

26 Aug, 2023 New Results from Post Hoc Analysis of APOLLO-B Phase 3 Study of Patisiran Presented during ESC 2023

02 Aug, 2023 Phase 3 Results From ENVISION Study of GIVLAARI® (givosiran) Published in the Journal of Hepatology

19 Jul, 2023 Phase 1 Results of Zilebesiran Published in the New England Journal of Medicine

17 Jul, 2023 Updated Phase 1 Results for ALN-APP Presented at 2023 Alzheimer’s Association International Conference

FOLLOW US